Last edition
News about "Endometriosis Market to Triple by 2034, Driven by "
Endometriosis Market to Triple by 2034, Driven by Novel Therapies and Rising Diagnoses: GlobalData
This robust growth is attributed to the expected launch of innovative therapies such as Kissei Pharmaceutical’s Yselty (linzagolix), a GnRH antagonist already available in Europe and soon launching in the US and Japan.
Endometriosis Market To Triple By 2034, Driven By | 04/07/2025 | By Darshana | 174
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members